Spots Global Cancer Trial Database for carcinoma of the appendix

Every month we try and update this database with for carcinoma of the appendix cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Interleukin-12 in Treating Patients With Cancer in the Abdomen	NCT00003046	Anal Cancer Colorectal Canc... Gallbladder Can... Gastric Cancer Pancreatic Canc...	Recombinant Int...	18 Years -	M.D. Anderson Cancer Center
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer	NCT00274885	Cancer	oxaliplatin management of t...	18 Years -	National Cancer Institute (NCI)
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer	NCT00903396	Anal Cancer Carcinoma of th... Colorectal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Gastrointestina... Liver Cancer Nausea and Vomi... Pancreatic Canc... Primary Periton... Small Intestine...	palonosetron hy... placebo	18 Years -	Alliance for Clinical Trials in Oncology
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer	NCT00005842	Cancer	trastuzumab tipifarnib	18 Years -	National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Cancer in the Abdomen	NCT00003046	Anal Cancer Colorectal Canc... Gallbladder Can... Gastric Cancer Pancreatic Canc...	Recombinant Int...	18 Years -	M.D. Anderson Cancer Center
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum	NCT00005860	Cancer	floxuridine leucovorin calc... oxaliplatin	18 Years -	National Cancer Institute (NCI)
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity	NCT00003548	Cancer	aminocamptothec...	18 Years -	NYU Langone Health
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)	NCT01126346	Advanced Malign... Carcinoma of th... Ovarian Sarcoma Ovarian Stromal... Pseudomyxoma Pe... Recurrent Colon... Recurrent Malig... Recurrent Ovari... Recurrent Ovari... Stage III Colon... Stage III Ovari... Stage III Ovari... Stage IV Colon ... Stage IV Ovaria... Stage IV Ovaria... Unspecified Chi...	HIPEC Orientati... Consultation wi... Questionnaires	-	Wake Forest University Health Sciences
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)	NCT00031681	Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas...	7-hydroxystauro... irinotecan hydr... diagnostic labo...	18 Years -	National Cancer Institute (NCI)
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)	NCT01126346	Advanced Malign... Carcinoma of th... Ovarian Sarcoma Ovarian Stromal... Pseudomyxoma Pe... Recurrent Colon... Recurrent Malig... Recurrent Ovari... Recurrent Ovari... Stage III Colon... Stage III Ovari... Stage III Ovari... Stage IV Colon ... Stage IV Ovaria... Stage IV Ovaria... Unspecified Chi...	HIPEC Orientati... Consultation wi... Questionnaires	-	Wake Forest University Health Sciences
Irinotecan and Capecitabine in Treating Patients With Solid Tumors	NCT00003867	Cancer	capecitabine irinotecan hydr...	18 Years - 120 Years	Montefiore Medical Center
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)	NCT01126346	Advanced Malign... Carcinoma of th... Ovarian Sarcoma Ovarian Stromal... Pseudomyxoma Pe... Recurrent Colon... Recurrent Malig... Recurrent Ovari... Recurrent Ovari... Stage III Colon... Stage III Ovari... Stage III Ovari... Stage IV Colon ... Stage IV Ovaria... Stage IV Ovaria... Unspecified Chi...	HIPEC Orientati... Consultation wi... Questionnaires	-	Wake Forest University Health Sciences
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer	NCT00005842	Cancer	trastuzumab tipifarnib	18 Years -	National Cancer Institute (NCI)
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer	NCT00087191	Advanced Adult ... Carcinoma of th... Fallopian Tube ... Gastrointestina... Localized Extra... Localized Gallb... Localized Gastr... Localized Resec... Localized Unres... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Primary Periton... Recurrent Adult... Recurrent Adult... Recurrent Colon... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Small... Recurrent Uteri... Regional Gastro... Small Intestine... Small Intestine... Small Intestine... Stage 0 Non-sma... Stage I Adult S... Stage I Colon C... Stage I Gastric... Stage I Non-sma... Stage I Ovarian... Stage I Ovarian... Stage I Pancrea... Stage I Rectal ... Stage I Uterine... Stage II Adult ... Stage II Colon ... Stage II Gastri... Stage II Non-sm... Stage II Ovaria... Stage II Ovaria... Stage II Pancre... Stage II Rectal... Stage II Uterin... Stage III Adult... Stage III Colon... Stage III Gastr... Stage III Ovari... Stage III Ovari... Stage III Pancr... Stage III Recta... Stage III Uteri... Stage IIIA Non-... Stage IIIB Non-... Stage IV Adult ... Stage IV Colon ... Stage IV Gastri... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Stage IV Uterin... Unresectable Ex... Unresectable Ga...	EF5 motexafin lutet... pharmacological...	18 Years -	National Cancer Institute (NCI)
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer	NCT00397384	Adenocarcinoma ... Adenocarcinoma ... Advanced Adult ... Carcinoma of th... Gastrointestina... Metastatic Gast... Metastatic Squa... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Colon... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Pancr... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Colon ... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Pancre... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Unresectable Ex... Unresectable Ga...	cetuximab erlotinib hydro... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Irinotecan and Capecitabine in Treating Patients With Solid Tumors	NCT00003867	Cancer	capecitabine irinotecan hydr...	18 Years - 120 Years	Montefiore Medical Center
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen	NCT00016380	Cancer	dexamethasone ondansetron quality-of-life...	16 Years - 120 Years	Canadian Cancer Trials Group
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)	NCT00031681	Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas...	7-hydroxystauro... irinotecan hydr... diagnostic labo...	18 Years -	National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Cancer in the Abdomen	NCT00003046	Anal Cancer Colorectal Canc... Gallbladder Can... Gastric Cancer Pancreatic Canc...	Recombinant Int...	18 Years -	M.D. Anderson Cancer Center
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)	NCT00031681	Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas...	7-hydroxystauro... irinotecan hydr... diagnostic labo...	18 Years -	National Cancer Institute (NCI)
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs	NCT04985357	Stage III Breas... Stage IV Breast... Stage III Lung ... Stage IV Lung C... AML Multiple Myelom... Carcinoma Carcinoma, Panc... Carcinoma of Lu... Carcinoma, Non-... Carcinoma Breas... Carcinoma Prost... Carcinoma, Hepa... Carcinoma, Rena... Carcinoma, Neur... Carcinoma, Smal... Carcinoma, Ovar... Carcinoma Bladd... Carcinoma of Es... Carcinoma Cervi... Carcinoma, Thym... Carcinoma, Duct... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of Un... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Malignant Pleur... Malignant Ascit... Mesothelioma Cholangiocarcin...		18 Years -	Travera Inc
Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer	NCT00019773	Carcinoma of th... Colorectal Canc... Small Intestine...	capecitabine oxaliplatin	18 Years -	National Cancer Institute (NCI)
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients	NCT00253383	Cancer	counseling inte... educational int... psychosocial as... quality-of-life...	18 Years -	Dartmouth-Hitchcock Medical Center
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen	NCT00016380	Cancer	dexamethasone ondansetron quality-of-life...	16 Years - 120 Years	Canadian Cancer Trials Group
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer	NCT00055705	Cancer	PV701	18 Years -	National Cancer Institute (NCI)
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity	NCT00003548	Cancer	aminocamptothec...	18 Years -	NYU Langone Health
Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer	NCT00458809	Carcinoma of th... Colorectal Canc... Primary Periton...	oxaliplatin	18 Years - 120 Years	Wake Forest University Health Sciences
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer	NCT00096083	Cancer	isolated perfus... melphalan	16 Years -	Delcath Systems Inc.
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)	NCT00031681	Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas...	7-hydroxystauro... irinotecan hydr... diagnostic labo...	18 Years -	National Cancer Institute (NCI)
Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer	NCT00310076	Carcinoma of th... Colorectal Canc...	thalidomide surgery	18 Years - 120 Years	Wake Forest University Health Sciences
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)	NCT05461430	Pleural Effusio... Ascites, Malign... Carcinoma Carcinoma, Hepa... Carcinoma, Rena... Carcinoma, Rena... Carcinoma, Smal... Carcinoma, Non-... Carcinoma, Panc... Carcinoma, Neur... Carcinoma, Thym... Carcinoma, Panc... Carcinoma Breas... Carcinoma, Ovar... Carcinoma Bladd... Carcinoma of Un... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of Es... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Cholangiocarcin... Melanoma Mesothelioma Pancreatic Canc...		18 Years -	Travera Inc

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: